Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

9.1K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

908
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
908
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

979
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
979

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biphasic oxygen-regulating cyanobacterial hydrogel for synergistic ischemic stroke gas therapy and post-stroke depression prevention.

Materials today. Bio·2026
Same author

Prophage-Derived Endolysin E1 Synergizes with Meropenem Against <i>Acinetobacter baumannii</i>.

Microorganisms·2026
Same author

Concurrent immunoradiotherapy with Toripalimab versus concurrent chemoradiotherapy with S-1 in older patients with esophageal squamous cell carcinoma: a retrospective cohort study.

Translational oncology·2026
Same author

Effect of a combined thermal protection strategy with plantar hot salt packs on preventing intraoperative hypothermia during knee arthroscopy: a randomized controlled trial.

Scientific reports·2026
Same author

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.

Signal transduction and targeted therapy·2026
Same author

Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2026

Related Experiment Video

Updated: Mar 21, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

66.3K

Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy.

Haihua Yang1, Linghai Yang2

  • 1Division of EndocrinologyZhengzhou Children's Hospital, Zhengzhou, Henan, China yhhua415@163.com linghai@uw.edu.

Journal of Molecular Endocrinology
|May 20, 2016
PubMed
Summary

The cyclic adenosine monophosphate (cAMP)/cAMP-dependent protein kinase (PKA) pathway is crucial for regulating glucose homeostasis. This review explores its role in various tissues and its potential for type 2 diabetes mellitus (T2D) treatment.

Keywords:
PKAdiabetesglucagonglucoseinsulin

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.8K

Related Experiment Videos

Last Updated: Mar 21, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

66.3K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K
Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.8K

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Physiology

Background:

  • Cyclic adenosine monophosphate (cAMP) acts as a vital intracellular second messenger in mammals, typically activated by G protein-coupled receptors (GPCRs).
  • The cAMP/cAMP-dependent protein kinase (PKA) signaling pathway plays a critical role in numerous physiological processes.
  • Dysregulation of this pathway is implicated in metabolic disorders such as type 2 diabetes mellitus (T2D).

Purpose of the Study:

  • To review recent genetic and pharmacological studies on the cAMP/PKA pathway's regulation of glucose homeostasis.
  • To examine the pathway's involvement across key metabolic tissues including the pancreas, liver, skeletal muscle, adipose tissue, and brain.
  • To discuss potential therapeutic strategies targeting the cAMP/PKA pathway for T2D research and treatment.

Main Methods:

  • Literature review of recent genetic and pharmacological studies.
  • Synthesis of findings on cAMP/PKA pathway regulation in glucose homeostasis.
  • Analysis of therapeutic strategies for T2D.

Main Results:

  • The cAMP/PKA pathway regulates glucose homeostasis at multiple levels, including hormone secretion, glucose uptake, and metabolic pathways like gluconeogenesis.
  • Studies highlight the pathway's significant role in the pancreas, liver, skeletal muscle, adipose tissue, and brain.
  • Genetic and pharmacological interventions targeting cAMP/PKA show promise for T2D research.

Conclusions:

  • The cAMP/PKA signaling pathway is a central regulator of glucose homeostasis across diverse mammalian tissues.
  • Understanding this pathway offers insights into the pathophysiology of T2D.
  • Targeting the cAMP/PKA pathway presents a viable strategy for developing novel T2D therapeutics.